At Septerna, we are building a pipeline of highly differentiated GPCR-targeted drug discovery and development programs built on our unique Native Complex Platform™.
We can now reach biologically validated, but historically undruggable GPCRs, as well as the vast majority of unexploited GPCRs still awaiting biological characterization and validation.
The Native Complex Platform™ puts Septerna in a unique position to overcome historical GPCR drug discovery barriers and build a pipeline of new and important medicines for patients.
